ArticleFrontiers in cell and developmental biology2026
Impact of intrauterine infusion of human umbilical cord blood mononuclear cells on reproductive outcomes in patients with thin endometrium undergoing frozen embryo transfer.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to assess the effects of intrauterine infusion of human umbilical cord blood mononuclear cells (HUCBMCs) on reproductive outcomes in patients with thin endometrium undergoing frozen embryo transfer (FET). Design: Prospective cohort study. Study Participants: This study enrolled 134 patients diagnosed with thin endometrium who underwent FET procedures between January 2022 and December 2023. The cohort was stratified into two groups: a treatment group receiving HUCBMCs infusion (n = 35) and a control group (n = 99). Methods: Participants were allocated into two groups: the HUCBMCs group and the control group, based on the administration of HUCBMCs intrauterine infusion. Reproductive outcomes were monitored for all participants. The primary outcome measure was live birth, while secondary outcomes encompassed endometrial characteristics (thickness, pattern, and endometrial-subendometrial (ES) blood flow distribution pattern), implantation rate, biochemical pregnancy, clinical pregnancy, ongoing pregnancy, miscarriage rate, and obstetric outcomes. Multivariable logistic regression analyses were employed to ascertain the independent effects of HUCBMCs. Results: No significant improvement in endometrial characteristics was noted following the infusion of HUCBMCs. Similarly, the live birth rate did not differ significantly between the groups, with the HUCBMCs group exhibiting a live birth rate of 27.6% (8 out of 29 patients), comparable to the control group 27.1% (19 out of 70 patients) ( Conclusion: Our findings indicate that although HUCBMCs infusion was deemed safe, there was no statistically significant improvement in reproductive outcomes between the HUCBMCs group and the control group. The miscarriage rate remained high among patients with thin endometrium. However, blastocyst transfer may be associated with a higher live birth rate compared to cleavage embryo transfer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.